ArticleAsian Pacific journal of cancer prevention : APJCP2025
Predictive and Prognostic Significance of Serum Neuron-Specific Enolase in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Gefitinib: A Prospective Study from South Egypt Cancer Institute.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alterations in peripheral blood inflammatory mediators, vascular endothelial growth factor, and serum tumor markers in advanced non-small cell lung cancer patients treated with bevacizumab combined with chemotherapy.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains the most lethal cancer in the world. Several predictive and prognostic biomarkers for non-small cell lung cancer (NSCLC) have emerged. Serum neuron-specific enolase (NSE) has been found to be elevated in up to 70% of patients with NSCLC. Prior retrospective studies have demonstrated conflicting results regarding the predictive and prognostic significance of baseline serum NSE in patients with metastatic NSCLC harboring epidermal growth factor receptor (EGFR) mutations who received tyrosine kinase inhibitors (TKIs). Our study aimed to evaluate the predictive and prognostic roles of pre-treatment serum NSE in patients with metastatic EGFR-mutated NSCLC planned to receive gefitinib therapy.
methodsIn this prospective cohort study, we enrolled patients with known metastatic EGFR-mutated lung adenocarcinoma who presented at the Medical Oncology and Hematological Malignancies Department, South Egypt Cancer Institute (SECI), Assiut University; during the period from January 1st, 2021 to December 31st, 2022; and were planned to receive gefitinib therapy. Pre-treatment serum NSE was measured. The cut-off date of our study was July 31st, 2024. Association of baseline serum NSE level with therapy response and survival outcomes was analysed.
resultForty eligible patients were enrolled. The median baseline serum NSE level was 9.0 ng/ml (range 6.0 - 15.3). Patients with high pre-treatment serum NSE level (higher than median level) were associated with significantly higher T and N clinical stages versus those with normal level (equal or less than median level). Regarding response rates, disease control rates (DCR) were significantly higher among those with normal serum NSE; whereas objective response rates (ORR) were similar in both groups. In terms of survival outcomes, high pre-treatment serum NSE was associated with worse progression-free survival (PFS) and overall survival (OS) outcomes.
conclusionBaseline serum NSE is an independent poor predictive and prognostic factor for patients with metastatic EGFR-mutated NSCLC receiving gefitinib therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.